U.S. Markets open in 7 hrs 55 mins
  • S&P Futures

    3,814.00
    +20.00 (+0.53%)
     
  • Dow Futures

    30,448.00
    +138.00 (+0.46%)
     
  • Nasdaq Futures

    11,701.50
    +77.75 (+0.67%)
     
  • Russell 2000 Futures

    1,779.20
    +11.20 (+0.63%)
     
  • Crude Oil

    87.73
    -0.03 (-0.03%)
     
  • Gold

    1,731.30
    +10.50 (+0.61%)
     
  • Silver

    20.86
    +0.32 (+1.54%)
     
  • EUR/USD

    0.9925
    -0.0061 (-0.6153%)
     
  • 10-Yr Bond

    3.7590
    0.0000 (0.00%)
     
  • Vix

    28.55
    -0.52 (-1.79%)
     
  • GBP/USD

    1.1364
    -0.0111 (-0.9682%)
     
  • USD/JPY

    144.5240
    +0.3250 (+0.2254%)
     
  • BTC-USD

    20,328.08
    +177.71 (+0.88%)
     
  • CMC Crypto 200

    462.00
    +3.59 (+0.78%)
     
  • FTSE 100

    7,052.62
    -33.84 (-0.48%)
     
  • Nikkei 225

    27,380.50
    +259.97 (+0.96%)
     

CytRx presents aldoxorubicin Phase 2b trial data

CytRx announced that Phase 2b trial data comparing first-line treatment with aldoxorubicin has been selected for oral presentation at the 2014 American Society for Clinical Oncology Annual Meeting. Aldoxorubicin is currently being studied in a pivotal, global Phase 3 clinical trial evaluating the efficacy and safety of aldoxorubicin as a second-line treatment for patients with STS under a Special Protocol Assessment with the FDA. CytRx is also conducting two Phase 2 clinical trials evaluating aldoxorubicin in patients with late-stage glioblastoma and HIV-related Kaposi’s sarcoma.